Interferon microneedle, as well as preparation method and application thereof

A technology of interferon and microneedle, applied in the field of interferon, can solve the problems of heart toxicity and side effects, and achieve the effect of drug safety, non-toxic side effects, and environmental friendliness

Inactive Publication Date: 2014-10-01
SHANGHAI JIAO TONG UNIV
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are surgical treatment, laser treatment, etc., but these methods have different degrees of toxic and side effects.
In 2008, "New England Journal of Medicine" reported that oral propranolol (propranolol) can play a very good effect, but oral propranolol has potential cardiotoxic side effects
There is no report on the application of interferon prepared into microneedles for the treatment of hemangioma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Interferon microneedle, as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Embodiment 1 Preparation of Dextran Interferon Microneedle

[0028] prescription:

[0029] Naturally derived interferon-alpha: 25mg

[0030] 40% (w / w) dextran solution: 250 μL

[0031] The preparation method is:

[0032] 25 mg of interferon was dissolved in 250 μL of 20% dextran solution, mixed evenly, and then the mixed solution was poured into a microneedle mold, then air-dried at 4°C, demoulded, and the interferon microneedle was prepared.

Embodiment 2

[0033] Embodiment 2 Preparation of Dextran Interferon Microneedles

[0034] prescription:

[0035] Recombinant Interferon-β: 50mg

[0036] 10% (w / w) dextran solution: 1ml

[0037] 10% PEG solution 10ml

[0038] The preparation method is:

[0039] Add 50 mg of interferon to 1 mL of 10% W / W dextran (Dex) solution by weight percentage, mix well, then add 10 mL of 10% W / W PEG solution, and vortex to form an emulsion. Stand still, and freeze-dry after the bubbles on the surface of the emulsion basically disappear. The lyophilized powder was washed with dichloromethane and dried to obtain interferon polysaccharide particles.

[0040] PLGA: 20% PLGA50g ethyl acetate solution

[0041] The above-mentioned interferon polysaccharide particles are mixed with the ethyl acetate solution of PLGA, then poured into the mold of the microneedle, dried and demoulded, and the microneedle is prepared.

Embodiment 3

[0042] Embodiment 3 prepares PVA interferon microneedle

[0043] Microneedle Prescription:

[0044] 20% PVA aqueous solution: 100mg

[0045] The preparation method is:

[0046] Add 20mg of PVA to 80mg of ultrapure water, heat to dissolve, then add 10mg of a mixture of interferon and trehalose (including 4mg of recombinant interferon-α, 6mg of trehalose), mix well by vortexing, and then pour the above solution into the microneedle The interferon microneedle is prepared after being dried and demoulded.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an interferon microneedle, as well as a preparation method thereof and application of the interferon microneedle in preparation of medicaments for treating hemangioma. The interferon microneedle comprises interferon which is one of naturally extracted interferon, gene recombinant expressed interferon, polyethylene glycol-modified interferon, glycosylation-modified interferon and human albumin fused interferon, wherein the interferon microneedle is prepared from the interferon and polymer; or the surface of the microneedle is coated with a layer of mixture of the interferon and auxiliaries keeping activity of the interferon to prepare the interferon microneedle. Compared with the prior art, the novel medical application of the interferon microneedle opens up a new application field, and the microneedle has the advantages of safe administration, no toxic or side effect, good compliance, patient pain relieving, low price and the like and can be easily accepted by patients.

Description

technical field [0001] The present invention relates to interferon, in particular to interferon microneedle, its preparation method and its use in the preparation of hemangioma medicine. Background technique [0002] Hemangioma is a common disease in children. The incidence rate of newborn infants is 2% to 3%, the incidence rate of 0 to 1 year old is about 10%, and the incidence rate of premature or mild neonates is about 20% to 30%. Currently there are surgical treatment, laser treatment, etc., but these methods have varying degrees of toxic and side effects. In 2008, "New England Journal of Medicine" reported that oral propranolol (propranolol) can play a very good effect, but oral propranolol has potential cardiotoxic side effects. Scientists set out to find new drugs to treat hemangiomas. [0003] Interferon (IFN) is a broad-spectrum antiviral agent, which does not directly kill or inhibit viruses, but mainly makes cells produce antiviral proteins through the action of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/21A61K9/00A61K47/34A61K47/38A61K47/36A61P35/00
Inventor 袁伟恩吴飞原明璐徐明新
Owner SHANGHAI JIAO TONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap